Isenberg D A, Manson J J, Ehrenstein M R, Rahman A
Centre for Rheumatology Research, Division of Medicine, University College London, London W1T 4JF, UK.
Rheumatology (Oxford). 2007 Jul;46(7):1052-6. doi: 10.1093/rheumatology/kem112. Epub 2007 May 11.
The year 2007 marks the 50th anniversary of the identification of antibodies to double-stranded (ds) DNA. Whilst widely regarded as synonymous with patients who have systemic lupus erythematosus (SLE), doubts have been raised about their significance and the extent to which they are genuinely part of the pathogenesis of the disease rather than being mere bystanders. Problems with assays used to detect them are still evident but they remain widely utilized both to help establish the diagnosis of SLE and to monitor the progress of the disease. This review explores each of these aspects and concludes that whilst some way short of ideal, their measurement remains a useful criterion for the disease and some of these antibodies do appear to be genuinely pathogenic. However, further research is needed to establish beyond 'reasonable doubt' whether they are merely part of the spectrum of anti-nucleosome antibodies, the precise mechanisms by which they 'exert' their pathogenic effects and to what extent blocking them would be a useful therapeutic goal.
2007年是双链(ds)DNA抗体被鉴定50周年。虽然双链DNA抗体被广泛认为是系统性红斑狼疮(SLE)患者的同义词,但人们对其意义以及它们在多大程度上是疾病发病机制的真正组成部分而非仅仅是旁观者提出了质疑。用于检测它们的检测方法仍存在明显问题,但它们仍被广泛用于帮助确立SLE的诊断和监测疾病进展。本综述探讨了这些方面,并得出结论:虽然远非理想,但它们的检测仍是该疾病的一个有用标准,其中一些抗体似乎确实具有致病性。然而,需要进一步研究以“排除合理怀疑”地确定它们是否仅仅是抗核小体抗体谱的一部分、它们“发挥”致病作用的确切机制以及阻断它们在多大程度上会成为一个有用的治疗目标。